Oxylabs, a web-scraping infrastructure company based in Lithuania, announced on July 10 that it had raised $130 million in its first external funding round, led by Warburg Pincus. The deal values the company at $3.6 billion. It is the company's first outside capital in a decade of operation. Not a Series A. Not a seed extension. The first money in, after ten years of building without it.
The numbers behind the raise tell the story more clearly than the round itself. Oxylabs reports more than $350 million in annual recurring revenue and over 350,000 customers worldwide. The company builds proxy networks and data-collection tools that power everything from ecommerce price monitoring to competitive analysis to AI model training. It reached those figures by reinvesting revenue rather than raising rounds. By the time Warburg Pincus arrived with $130 million from its $4 billion Capital Solutions Founders Fund, Oxylabs was already profitable and operating at a scale most venture-backed companies never reach.
The capital will fund expansion of its global proxy network and a new generation of web-scraping tools designed specifically for AI training data — a market that has exploded as large language models require vast amounts of structured web data to improve. No other investors were disclosed in the round, and the terms of the deal, including board seats and preferred stock provisions, were not made public. That silence on terms is itself telling. When a company raises from strength, it tends to share less about what it gave up.
This deal is a counternarrative to the dominant startup funding story. The default assumption in technology is that external capital accelerates growth and that bootstrapping limits it. Oxylabs followed the opposite sequence: build the business first, prove the economics, reach profitability, then raise capital from a position where you set the terms rather than accept them. A $3.6 billion valuation on a first round means the founders almost certainly retained far more ownership than a company that raised five progressive rounds to reach the same number. Each early round dilutes. Oxylabs skipped all of them.
Three things about this deal that matter for any business builder:
First, the product category matters. Web-scraping infrastructure is not glamorous. It does not generate viral demos, consumer press coverage, or TechCrunch launch-day profiles. But it sits underneath an enormous number of businesses that need web data — from ecommerce retailers tracking competitor pricing to research firms monitoring market movements to AI companies feeding training pipelines. Building a business in an essential but unglamorous layer of the technology stack is one of the most reliable paths to durable, compounding revenue.
Second, the timing of the raise was a choice, not a necessity. Oxylabs was already profitable with $350 million in ARR. The $130 million is growth capital, not survival capital. That distinction changes the entire relationship between founder and investor. When you raise because you want to accelerate, the conversation is about opportunity and shared upside. When you raise because you need to make payroll, the conversation is about dilution and control. The difference is visible in every term sheet.
Third, the AI training data market created a second growth curve for a company that already had a mature, profitable business. Oxylabs built its proxy infrastructure for one set of customers — ecommerce, market research, brand protection — and then watched an entirely new customer segment arrive that needed the exact same product for a different purpose. That kind of market-timing luck is not random. It rewards companies that build foundational tools rather than trend-chasing features, because foundational tools tend to find new uses that their builders never anticipated.
Ten years without outside money is not a strategy most founders would choose. But the terms you get when you finally ask tend to reflect how long you were willing to wait.